PD-L1 not only responds to the cGAS-STING pathway upon DNA damage, but also regulates cGAS-STING to induce inflammation. This ...
Tumors with a high level of TILs also have high expression of PD-L1, "but PD-L1-negative tumors ... nodes followed by the licensing of lymphatic cells that circulate back to the area of ...
Imfinzi reduced risk of death by 27% and reduced disease progression by 24% compared to patients receiving a placebo. 2. In ...
Immunotherapy has transformed cancer treatment, offering new avenues of hope for patients with advanced disease or limited ...
Atezolizumab by F. Hoffmann-La Roche for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Squamous Non-Small Cell Lung Cancer.
CTX-10726 is a tetravalent PD-1 x VEGF-A bispecific antibody discovered and engineered at Compass. CTX-10726 is designed to synergistically deliver VEGF-A blockade and checkpoint inhibition, ...
Our Bureau, Mumbai Thursday, December 26, 2024, 16:40 Hrs [IST] ...
Drug used to treat non-small cell lung cancer, liver cancer, gastric cancer, esophageal cancer, endometrial cancer and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback